It is that gaps are common, often go unnoticed, and that the many people using GLP-1s without supervision may be at higher, undetected risk
It says the provider prescribes the specific formulation based on medical history, biomarker data, and treatment goals
Regular lipid profile monitoring remains essential, with non-HDL cholesterol the preferred UK measurement for treatment response
This is the DermaVue clinical protocol developed across several thousand GLP-1 patients
But, really, theyre the same product
And what they were finding in analyzing these health records was that there was a dramatic reduction in the numbers of people on these medications that were actually developing these, addictions and not small reductions, but quite significant